AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Home Food Science Article
PDF (4.2 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese | Open Access

In Vitro Pro-angiogenic Activity of Porphyran Prepared from Porphyra yezoensis in Human Umbilical Vein Endothelial Cells (HUVECs) Model

Fengzhen FENG1 , Mingjing ZHENG1,2,3, Tao HONG1,2,3, Zhipeng LI1,2,3, Xiping DU1,2,3, Yanbing ZHU1,2,3, Hui NI1,2,3, Zedong JIANG1,2,3 ( )
College of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China
Fujian Provincial Key Laboratory of Food Microbiology and Enzyme Engineering, Xiamen 361021, China
Research Center of Food Biotechnology of Xiamen City, Xiamen 361021, China
Show Author Information

Abstract

In this study, the total sugar, protein, 3,6-anhydro galactose and sulfate contents, apparent molecular mass and monosaccharide composition of porphyran isolated from Porphyra yezoensis were analyzed. The pro-angiogenic activity and underlying mechanism of porphyran were further investigated using human umbilical vein endothelial cells (HUVECs) as an in vitro angiogenesis model. The effect of porphyran on the cell viability of HUVECs was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell adhesion and migration capacity were evaluated using cell adhesion and wound healing assays. The number of lumens formed by HUVECs was analyzed using in vitro tube formation assay. The expression levels of E-cadherin and N-cadherin in HUVECs were analyzed by Western Blotting, and the pro-angiogenic mechanism of porphyran in HUVECs was explored using specific inhibitors of mitogen-activated protein kinases (MAPKs) and vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors. The results showed that porphyran contained (77.48 ± 2.62)% total sugar, (3.24 ± 0.58)% protein, and (20.30 ± 1.06)% 3,6-anhydrogalactose as well as (20.78 ± 3.31)% sulfate groups. The apparent molecular mass of porphyran was 39.81 kDa. Porphyran was mainly composed of galactose, 3,6-anhydrogalactose and sulfate groups, suggesting it to be a sulfated galactan. Furthermore, porphyran treatment in the concentration range of 0-200 µg/mL had no significant toxicity no HUVECs, but instead promote cell proliferation, adhesion, migration, and vascular network formation. Further studies demonstrated that porphyran exerted its pro-angiogenic effect primarily by mediating the down-regulation of E-cadherin expression and the up-regulation of N-cadherin expression through the c-Jun N-terminal kinase (JNK) MAPK and VEGF receptor signaling pathways. In conclusion, porphyran has pro-angiogenic potential, which will provide a scientific basis for the development of porphyran as a novel pro-angiogenic factor and the precision nutrition-guided deep processing and high-value utilization of the red seaweed P. yezoensis.

CLC number: TS201.4 Document code: A Article ID: 1002-6630(2023)07-0001-09

References

【1】
【1】
 
 
Food Science
Pages 1-9

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
FENG F, ZHENG M, HONG T, et al. In Vitro Pro-angiogenic Activity of Porphyran Prepared from Porphyra yezoensis in Human Umbilical Vein Endothelial Cells (HUVECs) Model. Food Science, 2023, 44(7): 1-9. https://doi.org/10.7506/spkx1002-6630-20220922-226

560

Views

1

Downloads

0

Crossref

1

Scopus

1

CSCD

Received: 22 September 2022
Published: 15 April 2023
© Beijing Academy of Food Sciences 2023.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).